Natalizumab (Tysabri) for relapsing multiple sclerosis

Medical Letter on Drugs and Therapeutics

Volumn 47, Issue 1202, 2005, Pages 13-15

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; GLATIRAMER; INTERFERON BETA SERINE; NATALIZUMAB; PLACEBO; MONOCLONAL ANTIBODY;

ABDOMINAL PAIN; ADJUVANT THERAPY; ANAPHYLAXIS; ARTHRALGIA; CLINICAL TRIAL; CROHN DISEASE; DEPRESSION; DISEASE COURSE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG COST; DRUG ELIMINATION; DRUG ERUPTION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG POTENTIATION; DRUG TOLERABILITY; DYSPNEA; FATIGUE; HEADACHE; HUMAN; HYPOTENSION; INFECTION; MULTIPLE SCLEROSIS; RECURRENT DISEASE; RIGOR; SHORT SURVEY; URTICARIA; ARTICLE; BLOOD BRAIN BARRIER; CELL ADHESION; CONTROLLED CLINICAL TRIAL; DRUG EFFECT; INTRAVENOUS DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; BLOOD-BRAIN BARRIER; CELL ADHESION; HUMANS; INJECTIONS, INTRAVENOUS; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; RANDOMIZED CONTROLLED TRIALS; TREATMENT OUTCOME;

EID: 14544295401     PISSN: 0025732X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (9)

1. Beta interferons for multiple sclerosis. Med Lett Drugs Ther 2002; 44:88.
2. SA Rizvi and MA Agius. Current approved options for treating patients with multiple sclerosis. Neurology 2004; 63 suppl 6:S8.
3. WA Sheremata et al. A safety and pharmacokinetic study of intravenous natalizumab in patients with MS. Neurology 1999; 52:1072.
4. PW O'Connor et al. Randomized multicenter trial of natalizumab in acute MS relapses: clinical and MRI effects. Neurology 2004; 62:2038.
5. DH Miller et al. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2003; 348:15.
6. CM Dalton et al. Effect of natalizumab on conversion of gadolinium enhancing lesions to T1 hypointense lesions in relapsing multiple sclerosis. J Neurol 2004; 251:407.
7. N Tubridy et al. The effect of anti-α4 integrin antibody on brain lesion activity in MS. The UK Antegren Study Group. Neurology 1999; 53:466.
8. S Ghosh et al. Natalizumab for active Crohn's disease. N Engl J Med 2003; 348:24.
9. TL Vollmer et al. An open-label safety and drug interaction study of natalizumab (Antegren) in combination with interferon-beta (Avonex) in patients with multiple sclerosis. Mult Scler 2004; 10:511.